search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Insulin-induced microvascular dilatation during a physiological stimulus - Studies in hypertension and obesity.


- candidate number3125
- NTR NumberNTR1251
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR19-mrt-2008
- Secondary IDs08-2-031 MEC
- Public TitleInsulin-induced microvascular dilatation during a physiological stimulus - Studies in hypertension and obesity.
- Scientific TitleInsulin-induced microvascular dilatation during a physiological stimulus - Studies in hypertension and obesity.
- ACRONYMMicrovascular dilatation after endogenous induced hyperinsulinemia
- hypothesisWe hypothesize that oral glucose intake and consequently the endogenous induced hyperinsulinemia will lead to insulin-induced microvascular dilatation in healthy normotensive subjects. Furthermore, we suggest that the insulin-mediated microvascular dilatation, resulting from this fysiological induced hyperinsulinemia, will be less in hypertensive and obese subjects compared to healthy controls.
- Healt Condition(s) or Problem(s) studiedObesity, Hypertension, Microcirculation
- Inclusion criteria- Inclusion criteria healthy normotensive subjects:
1. 18-60 years
2. Caucasian
3. Blood pressure <140/90 mmHg

- Inclusion criteria obese normotensive subjects:
1. 18-60 years
2. Caucasian
3. Blood pressure <140/90 mmHg
4. BMI 30-38kg/m2

- Inclusion criteria hypertensive subjects:
1. 18-60 years
2. Caucasian
3. Untreated hypertension >140/90mmHg.
- Exclusion criteria- Exclusion criteria for healthy normotensive and hypertensive subjects:
1. Obesity (BMI>27kg/m2)
2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
3. Diabetes mellitus according to the criteria of the ADA
4. Smoking
5. Alcohol use >4U/day
6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
7. Pregnancy
8. Wearing contact lenses

- Exclusion criteria for normotensive obese subjects:
1. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
2. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
3. Smoking
4. Alcohol use >4U/day
5. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
6. Pregnancy
7. Wearing contact lenses
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingSingle
- controlPlacebo
- groupCrossover
- TypeSingle arm
- Studytypeintervention
- planned startdate 15-apr-2008
- planned closingdate15-apr-2009
- Target number of participants48
- InterventionsThe hypertensive subjects will be asked to discontinu the intake of antihypertensive medication 3 weeks prior to the study. All subjects will be asked to collect urine during 24hrs prior to the first study day. Microcirculation measurements:
1. perfused capillary density and functional capillary recruitment in the nailfold, visualized by a capillary microscope
2. endothelium- (in) dependent vasodilation of finger skin microcirculation, evaluated with laser Doppler measurements in combination with iontophoresis of acetyl-choline and sodium nitroprusside
3. densities and diameter of arterioles, capillaries and venules in the bulbar conjunctiva, measured with conjunctival microscopy.
The glucose sollution will be taken orally. During the visit several blood samples will be taken, blood pressure and heart rate will be monitored.
- Primary outcome- Functional recruitment of capillaries in the skin.
- Secondary outcome- Perfused capillary density in the nailfold.
- Endothelium- (in)dependent vasodilatation of finger skin microcirculation
- Density of arterioles, capillaries and venules in the bulbar conjunctiva.
- Diameter of arterioles and venules in the bulbar conjunctiva.
- Insulin sensitivity (HOMA-IR)
- TimepointsEach visit will take approx. 3,5 hours. During each visit 1 catheter will be inserted in the antecubital vein of the lower arm and 1 venous blood sample of 5 ml will be drawn. Next, a set of microcirculation measurements will be performed (t=0 min.)
On t=90 min. one venous blood sample of 5 ml and one venous blood sample of 1 ml will be drawn. And after this, the glucose or placebo solution will be taken orally.
On t=105 min., t=120 min., t=150 min. and t=120 min. 1 venous blood sample of 5 ml and 1 venous blood sample of 1 ml will be taken.
On t =120 min. a second set of microcirculation measurements will be performed. The catheter will be removed at t=210 min.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. A.J.H.M. Houben
- CONTACT for SCIENTIFIC QUERIESDr. A.J.H.M. Houben
- Sponsor/Initiator University Hospital Maastricht (AZM), Department of Internal Medicine
- Funding
(Source(s) of Monetary or Material Support)
University Hospital Maastricht (AZM), Department of Internal Medicine
- PublicationsN/A
- Brief summaryOne of mechanism involved in the insulin-mediated regulation of blood glucose levels is the vasodilatory response by resistance vessels and preterminal arterioles. These hemodynamic effects of insuline contribute to glucose uptake (for approx. 40%) and several studies demonstrated impaired insulin-induced hemodynamic effects in hypertension and obesity. However, in these studies the hyperinsulinemia was artificially induced by a hyperinsulinemic euglycemic clamp. Till so far it is unknown if these hemodynamic effects of insulin will also occur with a physiological stimulus. In this study we will examine if the insulininduced microvascular effects will occur after a physiological stimulus (i.e. a oral glucose tolerance test). With that the physiological importance of the insulin-induced microvascular dilatation can be elucidated. In this study we hypothesize that oral glucose intake and consequently the endogenous induced hyperinsulinemia will lead to insulin-induced microvascular dilatation in healthy normotensive subjects. Furthermore, we suggest that the insulin-mediated microvascular dilatation, resulting from this fysiological induced hyperinsulinemia, will be less in hypertensive and obese subjects compared to healthy controls.
Objectives:
1. Will the intake of glucose lead to insulin-induced microvascular dilatation in healthy subjects?
2. Is this insulin-induced microvascular dilatation after a physiological stimulus impaired in obese and hypertensive subjects compared to healthy controls?
Study design:
All subjects will bring 2 visits to the AZM. The following interventions will be applied:
- microcirculation measurement intake glucose sollution microcirculation measurement - microcirculation measurement intake placebo sollution microcirculation measurement
During the 2 visits 1 catheter will be inserted in the antecubital vein of the lower dominant arm. Subsequently a set of microcirculation measurements will be performed (t=0 min.). After this set of measurements (t=90 min.) subjects will drink a glucose- or placebo sollution. 30 minutes after intake (t=120 min.) a second set of microcirculation measurements will be performed. During the study days the heart rate and blood pressure will be monitored and 6 venous blood samples of 5 ml and 5 venous blood samples of 1 ml will be taken. The intake of glucose or placebo will be randomly assigned.
- Main changes (audit trail)
- RECORD19-mrt-2008 - 3-apr-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl